Kevin Lee, PhD, MBA
Kevin joined SV as a Venture Partner in 2020. He is Chief Executive Officer of Bicycle Therapeutics and Non-Executive Director of Mestag and NodThera Ltd. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK). Before joining GSK, Kevin lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.
Kevin holds a degree in pharmaceutical sciences from Nottingham University, and a PhD in pharmacology from Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, UK. Kevin also holds an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.